Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Research output: Contribution to journalArticle


Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.


  • Laurence Albiges
  • Tom Powles
  • Michael Staehler
  • Karim Bensalah
  • Rachel H. Giles
  • Milan Hora
  • Markus A. Kuczyk
  • Thomas B. Lam
  • Börje Ljungberg
  • Lorenzo Marconi
  • Axel S. Merseburger
  • Alessandro Volpe
  • Yasmin Abu-Ghanem
  • Saeed Dabestani
  • Sergio Fernández-Pello
  • Fabian Hofmann
  • Teele Kuusk
  • Rana Tahbaz
  • Axel Bex
External organisations
  • Queen Mary University
  • Ludwig-Maximilian University of Munich
  • University Medical Center Utrecht
  • University Hospital in Pilsen
  • Charles University in Prague
  • Hannover Medical School
  • University of Aberdeen
  • Umeå University
  • University Hospital of Coimbra
  • University Medical Center Schleswig-Holstein Campus Lubeck
  • University of Eastern Piedmont
  • Sheba Medical Center
  • Skåne University Hospital
  • University Hospital Cabueñes
  • Sunderby Hospital
  • Elbe kliniken
  • Antoni Van Leeuwenhoek Hospital
  • Institut Gustave Roussy
  • University of Paris-Saclay
  • Royal Free London NHS Foundation Trust
  • University of Rennes I
  • International Kidney Cancer Coalition (IKCC)
  • Aberdeen Royal Infirmary
  • University Hospital of Novara
  • Royal Free Hospital
  • University College London
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
  • Urology and Nephrology


  • Cabozantinib, Guidelines, Immune checkpoint inhibitors, Ipilimumab, Metastatic, Nivolumab, Pazopanib, Renal cell carcinoma, Sunitinib
Original languageEnglish
Pages (from-to)151-156
JournalEuropean Urology
Issue number2
Early online date2019 May 28
Publication statusPublished - 2019
Publication categoryResearch